Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)


Wednesday 21 October, 2020

Diurnal Group PLC

MAA for Alkindi submitted to Swissmedic

RNS Number : 7009C
Diurnal Group PLC
21 October 2020

21 October 2020



Diurnal Group plc

("Diurnal" or the "Company")


Market Authorisation Application for Alkindi® submitted to Swissmedic


Partner in Switzerland, EffRx Pharmaceuticals, expects market launch by 2022


Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the Company's marketing and distribution partner in Switzerland, EffRx Pharmaceuticals (EffRx), has submitted a Market Authorisation Application (MAA) to Swissmedic for the registration of Alkindi® (hydrocortisone granules in capsules for opening) in Switzerland.


The MAA submission to Swissmedic for Alkindi® is based on the European regulatory dossier and published clinical trial data, with EffRx expecting potential market launch in Switzerland by 2022. There are approximately 200 patients in Switzerland suffering from paediatric AI, providing an estimated total market opportunity for Alkindi® of approximately $1 million per annum. As previously announced under the terms of the agreement, EffRx will receive the exclusive rights to market and sell Alkindi® in Switzerland once registered.


Alkindi® is already approved and marketed in Europe and is the first preparation of hydrocortisone (the synthetic version of cortisol) specifically designed for use in children suffering from AI, including the related condition CAH.


Diurnal will provide EffRx with product for sale from its established European supply chain and forms part of the Company's ongoing strategy for commercialisation of its lead products by optimising market access outside of key European markets through entering marketing and distribution agreements with companies focused on niche and orphan conditions.


Martin Whitaker, CEO of Diurnal, commented:  

"We are pleased to see the submission of a MAA for Alkindi® in Switzerland by EffRx. Today's announcement is yet further validation of the quality of our products and broadens the future availability of Alkindi® outside our core markets in line with our global strategy. We look forward to working with EffRx to make Alkindi® available to patients suffering from paediatric AI in Switzerland."


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).


For further information, please visit or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell



Notes to Editors


About Alkindi® (hydrocortisone granules in capsules for opening)


Alkindi® is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenal insufficiency (AI). Alkindi® is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from diseases due to cortisol deficiency including paediatric AI and congenital adrenal hyperplasia (CAH). AI requires life-long treatment and Diurnal's novel approach to product development has the potential to significantly improve these young patients' lives. The European Commission has granted a paediatric use marketing authorisation (PUMA) for Alkindi® as replacement therapy of AI in infants, children and adolescents (from birth to <18 years old) in Europe.


Alkindi® is also approved in Israel and Australia.


Alkindi® is known as Alkindi® Sprinkle in the US and was approved by the US Food and Drug Administration (FDA) on 29 September 2020.


About Paediatric Adrenal Insufficiency


Paediatric AI, including the genetic condition CAH is a condition characterised by deficiency in cortisol, an essential hormone in regulating metabolism and the response to stress. The primary symptoms of AI are chronic fatigue and patients are at risk of adrenal crisis and death if they do not have adequate cortisol replacement. AI is either primary or secondary, with primary AI resulting from diseases intrinsic to the adrenal gland and secondary AI resulting from pituitary diseases where there is a failure of stimulation of the adrenal by the pituitary of the signalling hormone ACTH (adrenocorticotropic hormone).


About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.


For further information about Diurnal, please visit  


About EffRx Pharmaceuticals


EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialisation of prescription medications for niche and orphan indications. The business model is centred around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.


For further information about EffRx Pharmaceuticals, please visit


Date of Preparation: October 2020  Code: CORP-GB-0087


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t